Eris Lifesciences Toekomstige groei
Future criteriumcontroles 4/6
Eris Lifesciences zal naar verwachting groeien in winst en omzet met respectievelijk 30.7% en 16.2% per jaar. De winst per aandeel zal naar verwachting groeien met 30.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 18.8% zijn.
Belangrijke informatie
30.7%
Groei van de winst
30.7%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 17.8% |
Inkomstengroei | 16.2% |
Toekomstig rendement op eigen vermogen | 18.8% |
Dekking van analisten | Good |
Laatst bijgewerkt | 12 Nov 2024 |
Recente toekomstige groei-updates
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Recent updates
Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2027 | 38,502 | 7,188 | 9,553 | 11,113 | 9 |
3/31/2026 | 34,067 | 5,453 | 8,403 | 9,875 | 9 |
3/31/2025 | 30,061 | 3,807 | -9,707 | 6,931 | 9 |
9/30/2024 | 24,853 | 3,485 | 5,931 | 7,068 | N/A |
6/30/2024 | 22,469 | 3,803 | N/A | N/A | N/A |
3/31/2024 | 19,913 | 3,920 | 3,568 | 4,860 | N/A |
12/31/2023 | 18,406 | 3,864 | N/A | N/A | N/A |
9/30/2023 | 17,750 | 3,856 | -3,302 | 4,446 | N/A |
6/30/2023 | 17,298 | 3,824 | N/A | N/A | N/A |
3/31/2023 | 16,618 | 3,822 | -5,497 | 2,917 | N/A |
12/31/2022 | 15,663 | 3,970 | N/A | N/A | N/A |
9/30/2022 | 14,766 | 3,959 | 419 | 2,844 | N/A |
6/30/2022 | 13,746 | 3,940 | N/A | N/A | N/A |
3/31/2022 | 13,262 | 4,061 | 2,572 | 3,783 | N/A |
12/31/2021 | 12,993 | 3,941 | N/A | N/A | N/A |
9/30/2021 | 12,763 | 3,834 | 4,058 | 4,428 | N/A |
6/30/2021 | 12,482 | 3,728 | N/A | N/A | N/A |
3/31/2021 | 11,926 | 3,551 | 3,496 | 3,754 | N/A |
12/31/2020 | 11,625 | 3,432 | N/A | N/A | N/A |
9/30/2020 | 11,192 | 3,165 | 1,211 | 2,724 | N/A |
6/30/2020 | 10,744 | 3,015 | N/A | N/A | N/A |
3/31/2020 | 10,582 | 2,965 | 1,199 | 2,712 | N/A |
12/31/2019 | 10,252 | 2,943 | N/A | N/A | N/A |
9/30/2019 | 10,119 | 3,110 | 2,219 | 2,599 | N/A |
6/30/2019 | 9,920 | 3,036 | N/A | N/A | N/A |
3/31/2019 | 9,672 | 2,908 | 1,850 | 2,230 | N/A |
12/31/2018 | 9,851 | 2,925 | N/A | N/A | N/A |
9/30/2018 | 9,442 | 2,870 | N/A | N/A | N/A |
6/30/2018 | 9,212 | 2,945 | N/A | N/A | N/A |
3/31/2018 | 8,196 | 2,941 | N/A | 2,346 | N/A |
12/31/2017 | 8,026 | 2,800 | N/A | N/A | N/A |
9/30/2017 | 7,781 | 2,735 | N/A | N/A | N/A |
6/30/2017 | 7,277 | 2,505 | N/A | N/A | N/A |
3/31/2017 | 7,205 | 2,468 | N/A | 2,002 | N/A |
3/31/2016 | 5,967 | 1,112 | N/A | 1,315 | N/A |
3/31/2015 | 5,456 | 892 | N/A | 901 | N/A |
3/31/2014 | 5,088 | 704 | N/A | 896 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei ERIS ( 30.7% per jaar) ligt boven de spaarquote ( 6.7% ).
Winst versus markt: De winst van ERIS ( 30.7% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 18.1% per jaar).
Hoge groeiwinsten: De winst van ERIS zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van ERIS ( 16.2% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.5% per jaar).
Hoge groei-inkomsten: De omzet van ERIS ( 16.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ERIS zal naar verwachting over 3 jaar laag zijn ( 18.8 %).